Julius Ulrich, Tselmin Sergey, Fischer Sabine, Passauer Jens, Bornstein Stefan R
Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
Atheroscler Suppl. 2009 Dec 29;10(5):12-6. doi: 10.1016/S1567-5688(09)71803-3.
The first apheresis center in former German Democratic Republic was established in Dresden November 1990 following the reunification of Germany. We here summarize the activities of this center to date. From the center's establishment until the end of July 2009 13,291 sessions of therapeutic apheresis have been performed. Four LDL apheresis methods, namely DALI, Therasorb LDL, HELP and lipidfiltration, are available and several comparative studies of these methods have been published. In addition, we have established the Therasorb IG method and two rheophoresis methods (Rheofilter SR 20; TheraSorb-Rheo Adsorber). Currently we treat 53 high-risk patients with LDL apheresis, including 6 post- heart transplant patients and 5 patients with immunoadsorption. Since November 1990 we have seen a marked reduction in the number of new cardiovascular events by apheresis intervention, but they could not be totally prevented and 2 patients died despite LDL apheresis treatment. In our clinical experience all 4 LDL apheresis methods appear equally effective. However, it is an advantage to have the ability to switch methods in patients in whom one method was less effective or less well tolerated. We also successfully treated patients suffering from Evans' syndrome, pemphigus, urticaria vasculitis with monoclonal gammopathy IgM Type Kappa, lichen myxoedematosus or lupus erythematodes with immunoadsorption. The rheophoresis approach has been used in patients with age-dependent degeneration of the macula, sudden hearing loss, leg ulcers, and diabetic foot syndrome.
1990年德国统一后,前德意志民主共和国的首个血液成分单采中心于11月在德累斯顿成立。在此,我们总结该中心迄今为止的活动情况。从中心成立至2009年7月底,已进行了13,291次治疗性血液成分单采。有四种低密度脂蛋白血液成分单采方法,即DALI、Therasorb LDL、HELP和脂质过滤法,并且已发表了关于这些方法的多项比较研究。此外,我们还建立了Therasorb IG方法和两种流变吸附法(Rheofilter SR 20;TheraSorb - Rheo Adsorber)。目前,我们用低密度脂蛋白血液成分单采法治疗53例高危患者,其中包括6例心脏移植术后患者和5例免疫吸附患者。自1990年11月以来,通过血液成分单采干预,新发生的心血管事件数量显著减少,但仍无法完全预防,尽管进行了低密度脂蛋白血液成分单采治疗,仍有2例患者死亡。根据我们的临床经验,所有4种低密度脂蛋白血液成分单采方法似乎同样有效。然而,对于一种方法效果较差或耐受性较差的患者,能够切换方法是一个优势。我们还用免疫吸附法成功治疗了患有伊文氏综合征、天疱疮、伴有IgM κ型单克隆丙种球蛋白病的荨麻疹性血管炎、黏液性水肿性苔藓或红斑狼疮的患者。流变吸附法已用于患有年龄相关性黄斑变性、突发性听力损失、腿部溃疡和糖尿病足综合征的患者。